🎉 M&A multiples are live!
Check it out!

Entrada Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Entrada Therapeutics and similar public comparables like Julphar, Benevolent AI, and Vivoryon Therapeutics.

Entrada Therapeutics Overview

About Entrada Therapeutics

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.


Founded

2016

HQ

United States of America
Employees

183

Website

entradatx.com

Financials

LTM Revenue $161M

LTM EBITDA n/a

EV

-$63.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Entrada Therapeutics Financials

Entrada Therapeutics has a last 12-month revenue of $161M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Entrada Therapeutics achieved revenue of $211M and an EBITDA of $50.8M.

Entrada Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Entrada Therapeutics valuation multiples based on analyst estimates

Entrada Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $129M $211M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$0.3M $50.8M XXX XXX XXX
EBITDA Margin 0% 24% XXX XXX XXX
Net Profit -$94.6M -$6.7M XXX XXX XXX
Net Margin -73% -3% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Entrada Therapeutics Stock Performance

As of April 15, 2025, Entrada Therapeutics's stock price is $8.

Entrada Therapeutics has current market cap of $298M, and EV of -$63.0M.

See Entrada Therapeutics trading valuation data

Entrada Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$63.0M $298M XXX XXX XXX XXX $0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Entrada Therapeutics Valuation Multiples

As of April 15, 2025, Entrada Therapeutics has market cap of $298M and EV of -$63.0M.

Entrada Therapeutics's trades at -0.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Entrada Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Entrada Therapeutics and 10K+ public comps

Entrada Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$63.0M XXX XXX XXX
EV/Revenue -0.3x XXX XXX XXX
EV/EBITDA -1.2x XXX XXX XXX
P/E 4.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Entrada Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Entrada Therapeutics Valuation Multiples

Entrada Therapeutics's NTM/LTM revenue growth is -76%

Entrada Therapeutics's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Entrada Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Entrada Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Entrada Therapeutics and other 10K+ public comps

Entrada Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 63% XXX XXX XXX XXX
EBITDA Margin 24% XXX XXX XXX XXX
EBITDA Growth -15921% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -52% XXX XXX XXX XXX
Revenue per Employee $1.2M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 18% XXX XXX XXX XXX
R&D Expenses to Revenue 59% XXX XXX XXX XXX
Opex to Revenue 78% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Entrada Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Entrada Therapeutics M&A and Investment Activity

Entrada Therapeutics acquired  XXX companies to date.

Last acquisition by Entrada Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Entrada Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Entrada Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Entrada Therapeutics

When was Entrada Therapeutics founded? Entrada Therapeutics was founded in 2016.
Where is Entrada Therapeutics headquartered? Entrada Therapeutics is headquartered in United States of America.
How many employees does Entrada Therapeutics have? As of today, Entrada Therapeutics has 183 employees.
Who is the CEO of Entrada Therapeutics? Entrada Therapeutics's CEO is Mr. Dipal Doshi.
Is Entrada Therapeutics publicy listed? Yes, Entrada Therapeutics is a public company listed on NAS.
What is the stock symbol of Entrada Therapeutics? Entrada Therapeutics trades under TRDA ticker.
When did Entrada Therapeutics go public? Entrada Therapeutics went public in 2021.
Who are competitors of Entrada Therapeutics? Similar companies to Entrada Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Entrada Therapeutics? Entrada Therapeutics's current market cap is $298M
What is the current revenue of Entrada Therapeutics? Entrada Therapeutics's last 12-month revenue is $161M.
What is the current EV/Revenue multiple of Entrada Therapeutics? Current revenue multiple of Entrada Therapeutics is -0.4x.
What is the current revenue growth of Entrada Therapeutics? Entrada Therapeutics revenue growth between 2023 and 2024 was 63%.
Is Entrada Therapeutics profitable? Yes, Entrada Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.